Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Ingrid J. Guldvik; Verena Zuber; Peder R. Braadland; Helene H. Grytli; Håkon Ramberg; Wolfgang Lilleby; Bernd Thiede; Manuela Zucknick; Fahri Saatcioglu; Randi Gislefoss; Rune Kvåle; Anne George; Henrik Grönberg; Fredrik Wiklund; David E. Neal; Vincent J. Gnanapragasam; Kristin A. Taskén; Ian G. Mills

doi:10.1016/j.euros.2020.08.007

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Ingrid J. Guldvik^*, Verena Zuber, Peder R. Braadland, Helene H. Grytli, Håkon Ramberg, Wolfgang Lilleby, Bernd Thiede, Manuela Zucknick, Fahri Saatcioglu, Randi Gislefoss, Rune Kvåle, Anne George, Henrik Grönberg, Fredrik Wiklund, David E. Neal, Vincent J. Gnanapragasam, Kristin A. Taskén, Ian G. Mills

^*Corresponding author for this work

Patrick G Johnston Centre for Cancer Research

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

70 Downloads (Pure)

Abstract

High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

Original language	English
Pages (from-to)	51-60
Number of pages	10
Journal	European Urology Open Science
Volume	21
DOIs	https://doi.org/10.1016/j.euros.2020.08.007
Publication status	Published - 13 Oct 2020

Bibliographical note

Funding Information:
Funding/Support and role of the sponsor: This work has been supported by the Anders Jahre Foundation , University of Oslo , Movember Foundation , South-Eastern Norway Regional Health Authority , Oslo University Hospital , and the Norwegian Research Council , whereas the urology biorepository for the ProMPT (Prostate Cancer Mechanisms of Progression and Treatment) study is funded by the CRUK Cambridge Centre urology malignancy programme and the Cambridge NIHR Biomedical Campus.

Publisher Copyright:
© 2020 The Author(s)

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

Biomarker
Leucine-rich α-2-glycoprotein 1
Noninvasive
Prostate cancer

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euros.2020.08.007Licence: CC BY-NC-ND

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Copyright 2020 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 702 KBLicence: CC BY-NC-ND

Cite this

Guldvik, I. J., Zuber, V., Braadland, P. R., Grytli, H. H., Ramberg, H., Lilleby, W., Thiede, B., Zucknick, M., Saatcioglu, F., Gislefoss, R., Kvåle, R., George, A., Grönberg, H., Wiklund, F., Neal, D. E., Gnanapragasam, V. J., Taskén, K. A., & Mills, I. G. (2020). Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science, 21, 51-60. https://doi.org/10.1016/j.euros.2020.08.007

@article{3519598c7efb4af3a5ddbe621c3c4fca,

title = "Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification",

abstract = "High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.",

keywords = "Biomarker, Leucine-rich α-2-glycoprotein 1, Noninvasive, Prostate cancer",

author = "Guldvik, {Ingrid J.} and Verena Zuber and Braadland, {Peder R.} and Grytli, {Helene H.} and H{\aa}kon Ramberg and Wolfgang Lilleby and Bernd Thiede and Manuela Zucknick and Fahri Saatcioglu and Randi Gislefoss and Rune Kv{\aa}le and Anne George and Henrik Gr{\"o}nberg and Fredrik Wiklund and Neal, {David E.} and Gnanapragasam, {Vincent J.} and Task{\'e}n, {Kristin A.} and Mills, {Ian G.}",

note = "Funding Information: Funding/Support and role of the sponsor: This work has been supported by the Anders Jahre Foundation , University of Oslo , Movember Foundation , South-Eastern Norway Regional Health Authority , Oslo University Hospital , and the Norwegian Research Council , whereas the urology biorepository for the ProMPT (Prostate Cancer Mechanisms of Progression and Treatment) study is funded by the CRUK Cambridge Centre urology malignancy programme and the Cambridge NIHR Biomedical Campus. Publisher Copyright: {\textcopyright} 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = oct,

day = "13",

doi = "10.1016/j.euros.2020.08.007",

language = "English",

volume = "21",

pages = "51--60",

journal = "European Urology Open Science",

issn = "2666-1691",

publisher = "Elsevier B.V.",

}

Guldvik, IJ, Zuber, V, Braadland, PR, Grytli, HH, Ramberg, H, Lilleby, W, Thiede, B, Zucknick, M, Saatcioglu, F, Gislefoss, R, Kvåle, R, George, A, Grönberg, H, Wiklund, F, Neal, DE, Gnanapragasam, VJ, Taskén, KA & Mills, IG 2020, 'Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification', European Urology Open Science, vol. 21, pp. 51-60. https://doi.org/10.1016/j.euros.2020.08.007

TY - JOUR

T1 - Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

AU - Guldvik, Ingrid J.

AU - Zuber, Verena

AU - Braadland, Peder R.

AU - Grytli, Helene H.

AU - Ramberg, Håkon

AU - Lilleby, Wolfgang

AU - Thiede, Bernd

AU - Zucknick, Manuela

AU - Saatcioglu, Fahri

AU - Gislefoss, Randi

AU - Kvåle, Rune

AU - George, Anne

AU - Grönberg, Henrik

AU - Wiklund, Fredrik

AU - Neal, David E.

AU - Gnanapragasam, Vincent J.

AU - Taskén, Kristin A.

AU - Mills, Ian G.

N1 - Funding Information: Funding/Support and role of the sponsor: This work has been supported by the Anders Jahre Foundation , University of Oslo , Movember Foundation , South-Eastern Norway Regional Health Authority , Oslo University Hospital , and the Norwegian Research Council , whereas the urology biorepository for the ProMPT (Prostate Cancer Mechanisms of Progression and Treatment) study is funded by the CRUK Cambridge Centre urology malignancy programme and the Cambridge NIHR Biomedical Campus. Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/10/13

Y1 - 2020/10/13

N2 - High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

AB - High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

KW - Biomarker

KW - Leucine-rich α-2-glycoprotein 1

KW - Noninvasive

KW - Prostate cancer

U2 - 10.1016/j.euros.2020.08.007

DO - 10.1016/j.euros.2020.08.007

M3 - Article

AN - SCOPUS:85092458436

SN - 2666-1691

VL - 21

SP - 51

EP - 60

JO - European Urology Open Science

JF - European Urology Open Science

ER -

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this